Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „eculizumab“
Suchtreffer
Begriffe & Kennungen
Bekemv · 4.3 · Hypersensitivity to eculizumab or to any of the excipients listed in section 6.1.
Eintrag öffnenBekemv · 4.5 · No interaction studies have been performed. Based on the potential inhibitory effect of eculizumab on compleme
Eintrag öffnenBekemv · 4.8 · Antibodies to eculizumab were detected in patients with PNH and aHUS. As with all proteins there is a potentia
Eintrag öffnenBekemv · 4.8 · Cases of haemolysis have been reported in the setting of missed or delayed eculizumab dose in PNH clinical tri
Eintrag öffnenBekemv · 4.8 · Table 1 gives the adverse reactions observed from spontaneous reporting and in eculizumab completed clinical t
Eintrag öffnenBekemv · 4.8 · Table 1. Adverse reactions reported in eculizumab clinical trials, including patients with PNH, aHUS, refracto
Eintrag öffnenEculizumab
Eintrag öffnenEculizumab
Eintrag öffnenEculizumab
Eintrag öffnenEpysqli · 4.3 · Eculizumab therapy must not be initiated in patients (see section 4.4):
Eintrag öffnenEpysqli · 4.5 · Concomitant use of eculizumab with intravenous immunoglobulin (IVIg) may reduce effectiveness of eculizumab. C
Eintrag öffnenEpysqli · 4.5 · Concomitant use of eculizumab with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduc
Eintrag öffnenEpysqli · 4.5 · No interaction studies have been performed. Based on the potential inhibitory effect of eculizumab on compleme
Eintrag öffnenEpysqli · 4.8 · Antibodies to eculizumab were detected in patients. As with all proteins there is a potential for immunogenici
Eintrag öffnenEpysqli · 4.8 · Cases of haemolysis have been reported in the setting of missed or delayed eculizumab dose in PNH clinical tri
Eintrag öffnenEpysqli · 4.8 · Table 1 gives the adverse reactions observed from spontaneous reporting and in eculizumab completed clinical t
Eintrag öffnenEpysqli · 4.8 · Table 1: Adverse reactions reported in eculizumab clinical trials, including patients with PNH, aHUS, refracto
Eintrag öffnenSoliris · 4.3 · Hypersensitivity to eculizumab, murine proteins or to any of the excipients listed in section 6.1.
Eintrag öffnenSoliris · 4.5 · Concomitant use of eculizumab with intravenous immunoglobulin (IVIg) may reduce effectiveness of eculizumab. C
Eintrag öffnenSoliris · 4.5 · Concomitant use of eculizumab with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduc
Eintrag öffnen